antimycotics

The concern is great because the list and number of classes of antimycotics is short.

Interestingly and worryingly, there are very few antimycotics and there aren't enough new ones in the pharma pipeline.

If they are hiding inside human cells or tissues reaching them with antimycotics to a significant extent at all is tricky.

For fungi and yeast, there aren't enough antimycotics and they too are overused.

And antimycotics of all types and new classes are desperately to fight c.

There is a critical shortage of classes of antimycotics.

We need more antimycotics and phages quickly also.

The CDC discusses the concern [1] as linked by the author of the article, however, the distinction between antibiotics and antimycotics should have been made clearer and not used interchangeably.

We can reduce our risks by having strict international conventions on pathogen labs and engineering, eliminating high-density meat agriculture, and reducing overuse of antibiotics/antimycotics/antivirals.

It seems plausible in the near future with large piles of computing power to train LLMs against journals, give it access to data, drug/protein/ligand databases, and let it find and screen beneficial candidate molecules for critical need medications such as new classes of antibiotics and antimycotics, and rare degenerative diseases, perhaps including gene edits.

Isn't it the case that resistances to phages should be perhaps (an) order(s)-of-magnitude less likely for prokaryotes and fungi to evolve resistances compared to static compounds like antibotics/antimycotics because phages are probably the most abundant "almost life" parasitizing other microbes in the wild?